Capecitabine+Docetaxel (anthras pre-treated)
•
International phase III RCT: docetaxel
75
/capecitabine
1250
vs docetaxel
100
q21d
•
1L (53 and 31% pts per arm)
•
Primary endpoint: TTP (secondary: ORR, OS, safety and QoL)
O’Shaughnessy et al JCO 2002
ORR
AEs
•
The significantly superior TTP and survival achieved with the addition of capecitabine to
docetaxel 75 mg/m
2
, with
the manageable toxicity profile
, indicate that this combination
provides clear benefits over single-agent docetaxel 100 mg/m
2
. Docetaxel/capecitabine therapy
is an important treatment option for women with anthracycline-pretreated MBC
